Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET.

In addition to the fireside chat, the management team will hold one-on-one investor meetings Monday and Tuesday, August 5-6, 2024. If you are interested in meeting with the Tvardi Therapeutics management team during the conference, please reach out to BTIG.

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: hepatocellular carcinoma (NCT05440708) and idiopathic pulmonary fibrosis (NCT05671835). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter).

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.19
+5.71 (2.64%)
AAPL  262.89
+0.65 (0.25%)
AMD  239.27
-1.29 (-0.54%)
BAC  51.55
-0.49 (-0.95%)
GOOG  251.75
-5.27 (-2.05%)
META  733.73
+1.56 (0.21%)
MSFT  518.16
+1.37 (0.26%)
NVDA  181.54
-1.10 (-0.60%)
ORCL  275.50
-1.68 (-0.60%)
TSLA  446.50
-0.93 (-0.21%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.